Agili-C (an implant for treatment of cartilages)

2020: The announcement of Agili-C - an implant for treatment of cartilages

In the middle of October, 2020 the CartiHeal company provided Agili-C implant for treatment of artrozny and other injuries of a cartilage. Regulatory bodies of the USA gave to a new medical product the status of the innovation achievement capable to accelerate and transform development of orthopedics.

The program of search of the innovation achievements is designed to select those medical devices which provide more effective treatment or diagnosis of a life-threatening or serious, irreversible illness from lump. This program allows to accelerate registration of new inventions and allows patients to get timely access to these medical devices.

Agili-C implant from CartiHeal for treatment of the injured cartilages at arthritis is provided

CartiHeal already conducts reference clinical trial of IDE within which the implant of Agili-C is compared to the current surgical standard of treatment including microchanges and sanitation of a wound. The research is conducted in 26 centers in the USA, Europe and Israel and including 251 patients with osteoarthritis easy and moderate severity or with focal defects without artrozny changes. The company expects that final outputs of a research will appear in 2021.

The standard implant of CartiHeal is already registered for treatment of cartilaginous and bone and cartilaginous defects, both single, and multiple. In the whole Agili-C it was implanted to more than 500 studied patients with damage of a cartilage of a knee, ankle joint and joint of a thumb of foot in a series of the clinical trials conducted in the leading centers of Europe and Israel.

We are very glad that regulatory bodies gave to Agili-C implant the status of the innovation achievement, - the founder and the CEO of CartiHeal Nir Altschuler told. - We hope that it will accelerate process of registration of Agili-C as soon as we receive final outputs of the research IDE.[1]

Notes